Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Cullinan Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +6 vs. Q4 2022
- Shares held
- 32.3M
- −5.43M (−14.4%) vs. Q4 2022
- Total value
- $329.5M
- −$68.2M (−17.2%) vs. Q4 2022
- New holders
- 17
- 31 more added
- Sold out
- 11
- 34 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CGEM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 183 | $1.30B |
| Q1 2026 | 174 | $931.0M |
| Q4 2025 | 153 | $653.8M |
| Q3 2025 | 145 | $362.2M |
| Q2 2025 | 144 | $471.4M |
| Q1 2025 | 149 | $489.6M |
| Q4 2024 | 147 | $798.8M |
| Q3 2024 | 137 | $1.09B |
| Q2 2024 | 135 | $1.10B |
| Q1 2024 | 113 | $670.8M |
| Q4 2023 | 113 | $375.6M |
| Q3 2023 | 106 | $344.0M |
| Q2 2023 | 106 | $397.3M |
| Q1 2023 | 103 | $329.5M |
| Q4 2022 | 97 | $397.7M |
| Q3 2022 | 100 | $474.7M |
| Q2 2022 | 89 | $481.7M |
| Q1 2022 | 82 | $386.3M |
| Q4 2021 | 75 | $559.7M |
| Q3 2021 | 66 | $762.3M |
| Q2 2021 | 71 | $828.5M |
| Q1 2021 | 70 | $1.30B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Cullinan Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 3,196,701 | $32.7M | 1.20% | −4,312,358−57.4% | Reduced |
| CHI Advisors LLC | 3,349,460 | $34.3M | 9.10% | +31,916+1.0% | Added |
| MPM Oncology Impact Management LP | 7,648,268 | $78.2M | 20.33% | 00.0% | Unchanged |
| Woodline Partners LP | 0 | $0 | 0.00% | −195,839−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −101,900−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −79,918−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −41,980−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −16,927−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −10,412−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −10,249−100.0% | Sold out |
| Invesco Ltd. | 0 | $0 | 0.00% | −10,057−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −7,200−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −631−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −400−100.0% | Sold out |